Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home
During the government shutdown, only web sites supporting excepted functions will be updated. As a result, the information on this website may not be up to date and the agency may not be able to respond to inquiries.
Updates regarding government operating status and resumption of normal operations can be found at

PCD Logo


Diabetes Prevention in Hispanics: Report From a Randomized Controlled Trial

The number of people who received spot blood glucose tests was 5,820. Of these, 4,789 had normal blood glucose levels and were ineligible for participation. The remaining 1,031 were eligible for hemoglobin A1c testing (HbA1c). After testing, 601 people were excluded for the following reasons: HbA1c test results were normal (n = 189), the participant was lost to follow-up (n = 268), the participant declined to participate (n = 121), and other reasons (n = 23). The number randomly assigned to the trial arms was 430. Of these, 219 were assigned to the immediate intervention arm and 211 to the delayed intervention arm. A total of 53 people assigned to the immediate intervention were excluded for the following reasons: refused (n = 28), moved (n = 3), lost to follow-up (n = 18), ineligible (n = 3), missing data (n = 1). From the group assigned to the delayed intervention, 57 were excluded for the following reasons: refused (n = 22), moved (n = 12), lost to follow-up (n = 15), ineligible (n = 2), missing data (n = 6). One hundred and sixty-six participants in the immediate intervention and 154 in the delayed intervention were available for the efficacy evaluable analysis. Participants who were late giving a blood sample (55 in the immediate arm and 37 in the delayed arm) were excluded as part of a sensitivity analysis. The sensitivity analysis was conducted on data from 111 people in the immediate intervention and 117 in the delayed intervention arm.

Figure 1. Overview of the process for the randomized-controlled prevention trial of the Partnership for a Hispanic Diabetes Prevention Program. Abbreviation: HbA1c, hemoglobin A1c.

Return to article


This flowchart shows how and when trial participants entered the trial and received the intervention. After completing the baseline survey and having HbA1c tested, recruits were randomly assigned into 2 groups; one received the immediate intervention and one received the delayed intervention. Both groups had a second HbA1c test at 3 months postrandomization. Participants in the delayed intervention group began receiving the intervention at the trial’s 3-month time point. All participants completed a final survey and had a final HbA1c test at the 6-month time-point.

Figure 2. Timing of intervention and HbA1c measurements. Abbreviation: HbA1c, hemoglobin A1c.

Return to article

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

For Questions About This Article Contact The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #